Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) 2009 Jan;116(1):61-70
Date
05/08/2008Pubmed ID
18459944Pubmed Central ID
PMC2590620DOI
10.1042/CS20080039Scopus ID
2-s2.0-60549106716 (requires institutional sign-in at Scopus site) 75 CitationsAbstract
Hypertension and Type 2 diabetes are co-morbid diseases that lead to the development of nephropathy. sEH (soluble epoxide hydrolase) inhibitors are reported to provide protection from renal injury. We hypothesized that the sEH inhibitor AUDA [12-(3-adamantan-1-yl-ureido)-dodecanoic acid] protects the kidney from the development of nephropathy associated with hypertension and Type 2 diabetes. Hypertension was induced in spontaneously diabetic GK (Goto-Kakizaki) rats using AngII (angiotensin II) and a high-salt diet. Hypertensive GK rats were treated for 2 weeks with either AUDA or its vehicle added to drinking water. MAP (mean arterial pressure) increased from 118+/-2 mmHg to 182+/-20 and 187+/-6 mmHg for vehicle and AUDA-treated hypertensive GK rats respectively. AUDA treatment did not alter blood glucose. Hypertension in GK rats resulted in a 17-fold increase in urinary albumin excretion, which was decreased with AUDA treatment. Renal histological evaluation determined that AUDA treatment decreased glomerular and tubular damage. In addition, AUDA treatment attenuated macrophage infiltration and inhibited urinary excretion of MCP-1 (monocyte chemoattractant protein-1) and kidney cortex MCP-1 gene expression. Taken together, these results provide evidence that sEH inhibition with AUDA attenuates the progression of renal damage associated with hypertension and Type 2 diabetes.
Author List
Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JDMESH terms used to index this publication - Major topics in bold
AdamantaneAnimals
Antihypertensive Agents
Blood Glucose
Diabetes Mellitus, Experimental
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Disease Progression
Drug Evaluation, Preclinical
Enzyme Inhibitors
Epoxide Hydrolases
Hypertension
Insulin
Lauric Acids
Lipids
Male
NF-kappa B
Rats
Rats, Inbred Strains
